|
|
Volumn 389, Issue 10073, 2017, Pages 984-
|
|
Polypills: an essential medicine for cardiovascular disease
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTIHYPERTENSIVE AGENT;
ATORVASTATIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
RAMIPRIL;
CARDIOVASCULAR AGENT;
ASTHMA;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CAUSE OF DEATH;
CLINICAL DECISION MAKING;
DRUG INDUSTRY;
DRUG SAFETY;
EDITORIAL;
EPIDEMIC;
EVIDENCE BASED PRACTICE;
HEALTH CARE ACCESS;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LOW INCOME COUNTRY;
MEDICATION COMPLIANCE;
MIDDLE INCOME COUNTRY;
MIGRAINE;
NON COMMUNICABLE DISEASE;
PATIENT AUTONOMY;
PILL;
POLYPILL;
POPULATION;
PREMATURITY;
PRIMARY PREVENTION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SECONDARY PREVENTION;
DRUG COMBINATION;
CARDIOVASCULAR AGENTS;
CARDIOVASCULAR DISEASES;
DRUG COMBINATIONS;
HUMANS;
|
|
EID: 85015207476
PISSN: 01406736
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/S0140-6736(17)30695-5 Document Type: Editorial |
|
Times cited : (5)
|
|
References (0)
|